Refine by
Idiopathic Pulmonary Fibrosis Suppliers Serving Belarus
11 companies found
based inSilver Spring, MARYLAND (USA)
We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical ...
TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
Mechanism: Porcupine inhibitor. Area under investigation: idiopathic pulmonary fibrosis. Date commenced phase: Q4 2021. Estimated Filing Acceptance: Country US: EU: Japan: China. Additional ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro assessment of Fibroblast-to-Myofibroblast transition (FMT). Newcells offers a fast and reliable FMT assay service to evaluate the efficacy of anti-fibrotic compounds using high-content imaging. This customisable, high-throughput assay is ...
based inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, ...
based inBangkok, THAILAND
The Regeneration Center provides comprehensive and scientifically backed stem cell treatments for numerous conditions and degenerative diseases. Through years of research and clinical applications of modern cellular therapeutics our internationally ...
Several clinical studies have clearly demonstrated the benefits of stem cells. Peer-reviewed medical journals today are intent on finding the richest source of stem cells in the human body. Researchers have found that umbilical cord blood is rich ...
based inSaint Kevin`s, IRELAND
At Horizon, we believe science and compassion must work together to transform lives. Our mission to deliver medicines for rare, autoimmune and severe inflammatory diseases and provide compassionate support comes from our strong and simple philosophy ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic ...
based inDublin, IRELAND
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life. We offer a full range of consulting, clinical development and commercialisation services from a global network of offices in ...
Focused on the unique needs of device and diagnostics manufacturers, ICON has broad experience in supporting trials of respiratory disease and infectious disease affecting respiratory function. The prevalence of respiratory diseases will continue to ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
![Ibio - Model 100 - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNTA4Ny9wcm9kdWN0cy84NTMxMzQvMTI1MDg3XzJfMjAyMzAyMTMwNjEwNTM5ODQxNzI5X3Jhdy5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MTQzLCJoZWlnaHQiOjEwMn19fQ== "Ibio - Model 100 - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics")
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased ...
based inProvidence, RHODE ISLAND (USA)
Ocean Biomedical is a 21st century biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary ...
New therapeutic antibodies for effective treatment of NSCLC and other disorders. We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, OCX-253 was chosen because it stimulates the B-Raf ...
based inMontreal, QUEBEC (CANADA)
SCIREQ strives to make a strong impact on global pulmonary health by empowering scientists to better understand and eradicate lung diseases. The global burden of respiratory diseases is primarily driven by asthma, chronic obstructive pulmonary ...